Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Semaglutide mimics the action of the natural protein glucagon-like peptide 1(GLP-1), a hormone ... Ozempic, or semaglutide, is a GLP-1 agonist, meaning its molecules mimic the structure of GLP-1, ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

About The Study: This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a novel glucagon-like peptide-1 (GLP-1 ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic ...

today announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the glucagon-like peptide-1 receptor (GLP-1) agonist semaglutide administered ...